Anaphylaxis: Difference between revisions
(→DDX) |
No edit summary |
||
| Line 1: | Line 1: | ||
==Definition== | ==Background== | ||
===Definition=== | |||
Highly likely when ANY ONE of the following criteria is fulfilled: | Highly likely when ANY ONE of the following criteria is fulfilled: | ||
#Criterion 1 (90% of pts) | #Criterion 1 (90% of pts) | ||
| Line 20: | Line 20: | ||
####Less than (70 mmHg + [2 x age]) from 1 to 10 years | ####Less than (70 mmHg + [2 x age]) from 1 to 10 years | ||
####Less than 90 mmHg from 11 to 17 years | ####Less than 90 mmHg from 11 to 17 years | ||
===Course=== | |||
#Uniphasic (80-90%) | |||
##Symptoms peak within 30min-1hr after onset, resolves within 30min-1hr of receiving Tx | |||
#Biphasic (10-20%) | |||
##Uniphasic response, followed by asymptomatic period of hour or more, then return of symptoms | |||
##The second phase does not necessarily resemble the first! | |||
##Possible risk factors | |||
###Severe initial symptoms | |||
###Late administration of epi | |||
###Delayed resolution of initial symptoms | |||
##Little evidence that glucocorticoids blunt a biphasic presentation | |||
#Protracted (case reports) | |||
##Lasts hours to days without resolving completely | |||
==DDX== | ==DDX== | ||
| Line 30: | Line 44: | ||
#Other forms of shock | #Other forms of shock | ||
==Presentation== | ==Diagnosis== | ||
===Presentation=== | |||
* Cutaneous symptoms - 90% | * Cutaneous symptoms - 90% | ||
* Respiratory symptoms - 70% | * Respiratory symptoms - 70% | ||
| Line 59: | Line 74: | ||
###Methylprednisolone 125 mg IV (2mg/kg in peds) | ###Methylprednisolone 125 mg IV (2mg/kg in peds) | ||
###Three day PO course (biphasic reaction always occurs within 72hrs) | ###Three day PO course (biphasic reaction always occurs within 72hrs) | ||
==Disposition== | ==Disposition== | ||
Revision as of 08:22, 12 January 2012
Background
Definition
Highly likely when ANY ONE of the following criteria is fulfilled:
- Criterion 1 (90% of pts)
- Acute onset of an illness involving the skin, mucosal tissue, or both AND at least one of the following:
- Respiratory compromise
- Reduced BP or associated symptoms (syncope, dizziness)
- Acute onset of an illness involving the skin, mucosal tissue, or both AND at least one of the following:
- Criterion 2 (10-20% of pts)
- TWO OR MORE of the following that that occur rapidly after exposure to a LIKELY allergen for that pt
- Involvement of the skin-mucosal tissue (hives, swollen lips-tongue-uvula)
- Respiratory compromise
- Reduced BP or associated symptoms
- Persistent GI symptoms (vomiting, diarrhea, crampy abd pain)
- TWO OR MORE of the following that that occur rapidly after exposure to a LIKELY allergen for that pt
- Criterion 3
- Reduced BP after exposure to a KNOWN allergy for that pt (minutes to hours):
- Adults
- Systolic < 90 or > 30% from baseline
- Peds
- Less than 70 mmHg from 1 month up to 1 year
- Less than (70 mmHg + [2 x age]) from 1 to 10 years
- Less than 90 mmHg from 11 to 17 years
- Adults
- Reduced BP after exposure to a KNOWN allergy for that pt (minutes to hours):
Course
- Uniphasic (80-90%)
- Symptoms peak within 30min-1hr after onset, resolves within 30min-1hr of receiving Tx
- Biphasic (10-20%)
- Uniphasic response, followed by asymptomatic period of hour or more, then return of symptoms
- The second phase does not necessarily resemble the first!
- Possible risk factors
- Severe initial symptoms
- Late administration of epi
- Delayed resolution of initial symptoms
- Little evidence that glucocorticoids blunt a biphasic presentation
- Protracted (case reports)
- Lasts hours to days without resolving completely
DDX
- Generalized urticaria
- Angioedema
- Asthma exacerbation
- Anxiety attack
- MI
- Scombroidosis
- Other forms of shock
Diagnosis
Presentation
- Cutaneous symptoms - 90%
- Respiratory symptoms - 70%
- GI symptoms - 40%
- Cardiovascular symptoms - 35%
Treatment
- Epinephrine 1:1000 IM 0.3-0.5mg (0.3-0.5mL) Q5-15min
- Give as soon as possible
- Always IM initially
- Start epinephrine infusion 1:10,000 2-10µg/min if inadequate response to IM
- Peds
- IM - 0.01mg/kg/dose (max 0.5mg)
- IV infusion - 0.05-1 mcg/kg/min
- Oxygen
- Consider intubation if e/o airway edema
- NS bolus
- If unresponsive to Epi assume distributive shock (give NS 1-2L)
- Glucagon 1-2mg IV over 5 min followed by infusion of 5-15µg/min
- If on B-blocker AND unresponsive to epi
- Also consider:
- Albuterol: For bronchospasm resistant to IM epinephrine
- Antihistamines
- Only for sympton control (hives, itching) AFTER hemodynamically stable
- Diphenhydramine 25 to 50 mg IV
- Ranitidine 50 mg IV (minimal evidence to support this)
- Only for sympton control (hives, itching) AFTER hemodynamically stable
- Glucocorticoid: May blunt biphasic reaction
- Methylprednisolone 125 mg IV (2mg/kg in peds)
- Three day PO course (biphasic reaction always occurs within 72hrs)
Disposition
- Admit: Severe and moderate (especially if symptoms did not respond promptly to epi)
- Home: Symptom-free for at least 4hr
- Send home with an epi autoinjector!
See Also
Sources
- Brown SGA, Mullins RJ and Gold MS, Anaphylaxis: diagnosis and management, MJA 2006; 185: 283–289
- Ewan PW, ABC of allergies – Anaphylaxis, BMJ 1998; 316: 1442-1445
- Simons FER, Gu X, Simons KJ, Epinephrine absorption in adults: Intramuscular versus subcutaneous injection, J Allergy Clin Immunol 2001;108:871-3
- Lieberman P et al, The diagnosis and management of anaphyalxis: An updated practice parameter, J Allergy Clin Immunol 2005;115;3:S483-S523
- Sheikh A, Shehata YA, Brown SGA, Simons FER. Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock.Cochrane Database of Systematic Reviews2008, Issue 4. Art. No.: CD006312. DOI:10.1002/14651858.CD006312.pub2
- Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.
- Tintinalli's Emergency Medicine
